Quick Answer
Vicapsys Life Sciences, Inc. reported Net Income of -$1.18 million for fiscal year 2023.
Vicapsys Life Sciences, Inc. — Key Financials by Year
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Net Income | -$1.18M -20.0% |
-$984.8K -315.7% |
-$236.9K +69.1% |
-$765.8K +45.7% |
-$1.41M | — |
| Diluted EPS | -$0.03 +0.0% |
-$0.03 | — | — | — | — |
| Total Assets | $39.7K -44.9% |
$72.0K -87.9% |
$594.3K +47.1% |
$404.1K -42.1% |
$698.4K | — |
| Cash and Equivalents | $9.4K -33.2% |
$14.1K -93.5% |
$217.3K +17023.3% |
$1.3K -99.5% |
$264.2K | — |
| Stockholders Equity | -$1.93M -102.9% |
-$950.8K -681.6% |
-$121.7K +72.9% |
-$449.1K -248.7% |
$302.0K +219.0% |
-$253.7K |
| R&D Expense | $15.3K +16.6% |
$13.1K -26.0% |
$17.7K -82.7% |
$102.2K +3.2% |
$99.0K | — |
| Operating Income | -$1.05M -6.3% |
-$984.8K -192.3% |
-$336.9K +56.0% |
-$765.8K | — | — |
| Shares Outstanding | 32.07M +2.8% |
31.19M +57.9% |
19.75M +12.9% |
17.48M +0.0% |
17.48M | — |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Net Income | September 30, 2024 | -$235.5K | +2.0% | -23.9% |
| Diluted EPS | September 30, 2024 | -$0.01 | +0.0% | +0.0% |
| Total Assets | September 30, 2024 | $89.6K | -57.0% | +125.9% |
| Cash and Equivalents | September 30, 2024 | $89.6K | +67.3% | +850.6% |
| Stockholders Equity | September 30, 2024 | -$2.65M | -98.3% | -8.2% |
| R&D Expense | September 30, 2024 | $3.7K | +14.7% | -62.5% |
| Operating Income | September 30, 2024 | -$198.9K | -13.4% | -9.4% |
| Shares Outstanding | September 30, 2024 | 32.37M | +0.9% | +0.9% |
- Vicapsys Life Sciences, Inc. reported Net Income of -$1.18 million for fiscal year 2023.
- Vicapsys Life Sciences, Inc. showed a decrease of -20.0% in Net Income compared to the prior fiscal year.
- Vicapsys Life Sciences, Inc. reported Diluted EPS of $0.03 per share (loss) for fiscal year 2023.
- Vicapsys Life Sciences, Inc. showed an increase of +0.0% in Diluted EPS compared to the prior fiscal year.
- Vicapsys Life Sciences, Inc. reported Total Assets of $39.7 thousand for fiscal year 2023.
- Vicapsys Life Sciences, Inc. showed a decrease of -44.9% in Total Assets compared to the prior fiscal year.
- Vicapsys Life Sciences, Inc. reported Cash and Equivalents of $9.4 thousand for fiscal year 2023.
- Vicapsys Life Sciences, Inc. showed a decrease of -33.2% in Cash and Equivalents compared to the prior fiscal year.
- Vicapsys Life Sciences, Inc. reported Stockholders Equity of -$1.93 million for fiscal year 2023.
- Vicapsys Life Sciences, Inc. showed a decrease of -102.9% in Stockholders Equity compared to the prior fiscal year.
- Vicapsys Life Sciences, Inc. reported R&D Expense of $15.3 thousand for fiscal year 2023.
- Vicapsys Life Sciences, Inc. showed an increase of +16.6% in R&D Expense compared to the prior fiscal year.
- Vicapsys Life Sciences, Inc. reported Operating Income of -$1.05 million for fiscal year 2023.
- Vicapsys Life Sciences, Inc. showed a decrease of -6.3% in Operating Income compared to the prior fiscal year.
- Vicapsys Life Sciences, Inc. reported Shares Outstanding of 32.07 million shares for fiscal year 2023.
- Vicapsys Life Sciences, Inc. showed an increase of +2.8% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: